Suppr超能文献

[现代青光眼治疗中的激光小梁成形术——综述]

[Laser Trabeculoplasty in Modern Glaucoma Therapy - a Review].

作者信息

Greslechner Roman, Spiegel Detlev

机构信息

Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg.

出版信息

Klin Monbl Augenheilkd. 2019 Oct;236(10):1192-1200. doi: 10.1055/a-0577-7925. Epub 2018 Apr 11.

Abstract

BACKGROUND

Laser trabeculoplasty (LTP) is a well established treatment modality in the management of chronic open angle glaucoma. Nonetheless there is much variation in practice.

METHODS

A literature search in the PubMed database was conducted and the most important evidence-based results were summarised.

RESULTS

Argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) are safe and effective treatment modalities, achieving an IOP reduction of 20 - 30%. Similar success rates have been reported for both procedures. A 50% rate of failure occurs after 2 - 5 years. Repeat-ALT is associated with a lower IOP decrease and a shorter duration of treatment effect. Repetition of SLT after initial SLT seems to be associated with loss of efficiency as well. SLT has been shown to be successful after initial ALT, whereas there are no data on ALT after initial SLT. For advanced glaucoma on maximum medical therapy, low success rates have been reported with regard to additional interventions.

CONCLUSION

LTP is a good option for initial and adjunctive treatment. In advanced glaucoma on maximum medical therapy, low target pressures are needed, and filtering surgery has to be considered.

摘要

背景

激光小梁成形术(LTP)是慢性开角型青光眼治疗中一种成熟的治疗方式。然而,实际操作中存在很大差异。

方法

在PubMed数据库中进行文献检索,并总结最重要的循证结果。

结果

氩激光小梁成形术(ALT)和选择性激光小梁成形术(SLT)都是安全有效的治疗方式,可使眼压降低20%-30%。两种手术的成功率相似。2至5年后失败率为50%。重复ALT与眼压降低幅度较小和治疗效果持续时间较短相关。初次SLT后重复SLT似乎也与效率降低有关。已证明初次ALT后SLT是成功的,而初次SLT后ALT则没有相关数据。对于接受最大药物治疗的晚期青光眼,额外干预的成功率较低。

结论

LTP是初始治疗和辅助治疗的良好选择。对于接受最大药物治疗的晚期青光眼,需要较低的目标眼压,并且必须考虑滤过手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验